Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics Stock Forecast

Stock Price Forecast

The 2 analysts that cover Atara Biotherapeutics stock have a consensus rating of "Hold" and an average price target of $8.50, which forecasts a -9.09% decrease in the stock price over the next year. The lowest target is $4.00 and the highest is $13.

Price Target: $8.50 (-9.09%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$4.00	$8.50	$13	$13
Change	-57.22%	-9.09%	+39.04%	+39.04%

Analyst Ratings

The average analyst rating for Atara Biotherapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	2	0	0	0	0	1
Buy	0	0	0	0	0	0
Hold	1	2	2	2	2	0
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	1
Total	4	3	3	3	3	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
John Newman Canaccord Genuity	Canaccord Genuity	Hold → Strong Buy Upgrades $6 → $13	Hold → Strong Buy	Upgrades	$6 → $13	+39.04%	May 8, 2026
Ilya Zubkov Freedom Broker	Freedom Broker	Strong Buy → Strong Sell Downgrades $16 → $4	Strong Buy → Strong Sell	Downgrades	$16 → $4	-57.22%	Jan 21, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Strong Buy → Hold Downgrades $25 → $6	Strong Buy → Hold	Downgrades	$25 → $6	-35.83%	Jan 13, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $17 → $25	Strong Buy	Maintains	$17 → $25	+167.38%	Dec 19, 2025
Ilya Zubkov Freedom Broker	Freedom Broker	Strong Sell Maintains $13 → $16	Strong Sell	Maintains	$13 → $16	+71.12%	Jul 28, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

31.86M

Decreased by -73.62%

from 120.77M

Revenue Next Year

47.07M

Increased by 47.76%

from 31.86M

EPS This Year

-1.15

from 2.57

EPS Next Year

-1.29

from -1.15

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	20.34M	63.57M	8.57M	128.94M	120.77M	31.86M	47.07M
Revenue Growth	-	212.55%	-86.52%	1,404.02%	-6.34%	-73.62%	47.76%
EPS	-90.78	-55.96	-65.19	-11.41	2.57	-1.15	-1.29
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	6	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	63.0M	86.1M
Avg	31.9M	47.1M
Low	11.5M	10.1M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	-47.8%	170.3%
Avg	-73.6%	47.8%
Low	-90.5%	-68.3%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	-0.85	-1.11
Avg	-1.15	-1.29
Low	-1.42	-1.44

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.